Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: support stimulates sustainability as I continue heightened analysis

April 18, 2023 7:45am

The support level represents a price point that an asset struggles to fall below over a given time period. Support levels can be visualized using different technical indicators or simply by drawing a line connecting the lowest lows for the period. Applying trendlines or incorporating moving averages provides a more dynamic view of support.

Pre-open indications: 6 Sell into Strength, 1 Positive and 1 Negative Indications

Q1/23 Earnings: Sage Therapeutics (SAGE) reports Tuesday - 5/2

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.

The 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday …

Dow futures are UP +0.41% or (+139 points), S&P futures are UP +0.41% or (+17 point) and NASDAQ futures are UP +0.58% or (+76 points) early in the pre-open – so far

Stock futures rose Tuesday,

European markets were higher,

Asia Pacific markets trade mixed.

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes finished higher during Monday sessions

Economic Data Docket: housing starts and building permits data. March housing starts are expected to fall 3.4% to 1.40 million units.

In global economic news, China GDP rose at a 4.5% pace in the first quarter the highest level in a year and more than the 4% estimate. <CNBC>

Monday’s (4/17) … RegMed Investors’ (RMi) closing bell: “sector share pricing rises after weeks of fear and dread. Chug, chug, huff, huff and puff, puff just like the “The Little Engine that Could.” … https://www.regmedinvestors.com/articles/12918

Ebb and flow:

Q2/23 – 1 holiday, 4 positive close and 6 negative closes

Q1/23 –

· March – ended with 10 positive and 13 negative closes

· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

· January – 2 holidays, 11 positive and 9 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Sell into Strength:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed down -$0.97 after Friday’s +$2.49 with a positive +$0.11 or +0.35% pre-open indication,

Chinook Therapeutics (KDNY) closed up +$1.24 with a positive +$0.43 or +1.99% aftermarket indication,

CRISPR Therapeutics CRSP) closed up +$3.98 after Friday’s -$0.25 and Thursday’s +$7.09 with a positive +$0.71 or +1.31% pre-open indication

Intellia Therapeutics (NTLA) closed up +$1.09 after Friday’s -$0.95 and Thursday’s +$4.53 with a positive +$0.10 or +0.25% pre-open indication,

Ionis Pharmaceuticals (IONS) closed up +$0.78 after Friday’s -$0.56 and Thursday’s +$0.97 with a positive +$0.04 or +0.11% pre-open indication,

Vericel (VCEL) closed up +$0.87 with a positive +$0.05 or +0.16% aftermarket indication.

Positive Indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Agenus (AGEN) closed down -$0.05 with a positive +$0.06 or +4.14% pre-open indication,

Negative Indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Verve Therapeutics (VERV) closed up +$0.74 with a positive -$0.28 or -1.77% pre-open indication,

The BOTTOM LINE: I try to keep it simple and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Reiterating, “A SUSTAINABLE uptrend is needed to get credibility BACK into the sector’s investment”

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!

Reiterating (from last night’s post):

· It’s all about expecting a ROTATION and it came; so, WHAT is Next – I believe SELL into STRENGTH – the future is unclear and it’s earning season … AGAIN.

· Uncertainty over short-run share pricing expectations continues to be notably elevated, indicating that the recent volatility in expected year-ahead inflation is likely to continue.

· I HATE to be a doom and gloomed, the Cboe Volatility Index, or “fear gauge,” marked its lowest close on Friday in more than a year. Monday the VIX was low, while cell and gene therapy sector rebounded after being oversold sine months beginning even with a few positive closes.

Reviewing the last weeks and Monday’s metrics:

· Monday, the IBB was up +0.86% and the XBI was up +4.69%,

· Friday, the IBB was down -0.86% and the XBI was down -1.56%

· Thursday, the IBB was up +2.31% and the XBI was up +4.46%

· Wednesday, the IBB was down -0.11% and the XBI was down -1.08%

· Tuesday, the IBB was up +0.27% and the XBI was up +0.98%

· Monday, the IBB was down -0.53% and the XBI was down -0.94%

At ANY time, this week, be ready to take partial profits and exit losers.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.